Category Archives: Business of Medicine

MEDLAB Series Europe, 13-15 Sep 2017, will cover Point of Care Testing (POCT), Histopathology, Lab Management, Microbiology and Haematology

Spain, 04-May-2017 — /EuropaWire/ — After many years of operating successful MEDLAB events around Africa, Asia and the Middle East, Informa Life Sciences Exhibitions, the worlds leading publishing and exhibitions company, has announced that the MEDLAB Series will be expanding its presence into Europe. Taking place at the Barcelona Congress Centre in Barcelona, Spain, from 13-15 September 2017, more than 3,000 industry professionals are expected to attend Europe’s leading event for laboratory management and diagnosis.

With the European In-Vitro Diagnostics (IVD) market expected to reach USD 15.5 billion by 2024, a platform such as MEDLAB presents a huge opportunity for global laboratory industry leaders, including manufacturers, dealers and distributors, to make inroads into the European market. Housing international exhibitors and covering 2,000 sqm of exhibition space, MEDLAB Europe will give visitors from across the world an opportunity to access cutting-edge laboratory products, next-generation technology, innovative services and world-class educational content.

According to Tom Coleman, Group Exhibition Director, MEDLAB Series: “The launch of MEDLAB Europe is in line with our global expansion strategy for our MEDLAB series of events. The increasing prevalence of chronic diseases, rising geriatric population coupled with the rising awareness towards early diagnosis, has positioned the European IVD and medical laboratory market as a critical market for manufacturers, services providers, and dealers and distributors from across the globe. MEDLAB Europe will generate substantial value for our customers and partners by driving further product innovation and deeper engagement in these specific markets.”

Over the four-day event, MEDLAB Europe will also offer a multi-disciplinary congress tackling current challenges and developments key to the European market, and leveraging the true potential of laboratory testing to dramatically improve patient outcomes across the continent.

The conference programme covers five main tracks including Point of Care Testing (POCT), Histopathology, Lab Management, Microbiology and Haematology. From new methods of effective lab management to the development of techniques in detecting diseases, the conferences will also review the expanding role of the laboratory medicine and discuss partnership between a clinician and a lab professional in providing delivery of care to every patient.

“The scientific programme at MEDLAB has been carefully designed in collaboration with some of the brightest minds in the medical laboratory industry in order to have a real impact on improving the health and wellbeing of patients across the region,” said Coleman.

For more information about the MEDLAB Europe Exhibition & Congress, please visit: www.medlabeurope.com.

SOURCE: EuropaWire

Multispectral Optoacoustic Tomography (MSOT) can now more reliably detect early stages of inflammation

GERMANY, Mar-30-2017 — /EPR HEALTHCARE NEWS/ — Ulcerative colitis and Crohn’s disease are the most common inflammatory bowel diseases (IBD). Globally, more than 4 million people suffer from recurring inflammation of the intestinal mucosa. To date, non-invasive methods have not been able to detect these forms of IBD reliably. Researchers at the University Hospital Erlangen (Germany) have now shown for the first time how Multispectral Optoacoustic Tomography (MSOT) can more reliably detect early stages of inflammation when compared with other non-invasive diagnostic methods. These results have recently been published in the New England Journal of Medicine.

Evaluating the inflammatory activity of the intestines early and accurately helps to prevent complications associated with IBD and guide an optimal therapy regime. Currently, doctors frequently rely on an invasive endoscopy procedure to assess the intestinal mucosa of patients with IBD. Additionally, non-invasive imaging methods are increasingly used in the clinic. For example, ultrasound allows clinicians to examine the structure, thickness and blood perfusion of the intestinal wall with changes in perfusion patterns indicating an onset of inflammation.

“With the MSOT procedure, we additionally use laser light, by which we can detect inflammation earlier than previously possible with ultrasound”, explains Prof. Dr. Maximilian Waldner, Professor at the University Hospital Erlangen. “The earlier we detect signs of an upcoming flare – i.e., a change in blood content – the quicker we can react and start a preventive treatment”. The MSOT technology was developed by iThera Medical in Munich, and was first used on IBD patients last year.

The researchers of the University Hospital Erlangen have recently published their results in the renowned New England Journal of Medicine. “We examined 108 patients with Crohn’s disease using the MSOT technology and compared the results to established non-invasive diagnostic procedures as well as endoscopy and histology”, says Prof. Waldner. “We were able to demonstrate that hemoglobin values in the tissue measured with MSOT indicate very accurately the inflammatory activity in the intestines. The method appears to be superior to other non-invasive procedures, as MSOT for the first time was able to detect even low levels of inflammation without having to perform endoscopy”.

Dr. Ferdinand Knieling, a physician at the University Hospital Erlangen, adds: “We are hoping that this principle can be applied to many applications and, in particular, also be used to enable safe evaluations of children and adolescents. With this new examination method, many of the currently invasive procedures might become obsolete.”

In optoacoustic imaging, the physician scans the intestines transabdominally through the skin, applying pulsed laser light in the near-infrared region. The energy of the light absorbed in tissue is converted into acoustic signals which are then acquired by an ultrasound detector. Christian Wiest, CEO of iThera Medical, comments: “MSOT is a new diagnostic imaging modality that can detect changes in tissue composition associated with a variety of diseases, without the use of contrast agents. The technology has already been applied in other clinical feasibility studies, e.g. for the detection of melanoma metastasis in sentinel lymph nodes or for the assessment of suspicious breast lesions”.

The results of the IBD study at the University Hospital Erlangen were published on March 30th 2017 in the New England Journal of Medicine (Volume 376, Issue 13, pg.1292-1294).

SOURCE: EuropaWire

Global leader in serialization solutions Systech to attend the annual pharmaceutical congress CPhI Worldwide in Barcelona, 4 – 6 Oct 2016

systech_international_slogo_europawireBRUSSELS, 28-Sep-2016 — /EuropaWire/ — Systech International, a global leader in brand protection technologies, will partner with Sharp Packaging and SINEL SYSTEMS, part of the Autajon Group, at CPhI Worldwide, the annual pharmaceutical congress held in Barcelona from 4 – 6 October 2016.

Systech will be part of Sharp’s panel discussion addressing delegates on the theme of “Serialization: Optimizing Your Supply Chain Means Optimizing Your Partners.” The presentation will explore the critical path to supply chain readiness, risk assessment, benchmarking and serialization risk mitigation options. The briefing will take place in the Pharma Insight Briefing room on Tuesday, 4 October 2016 at 11:30am CEST.

Systech will also showcase its UniSeries™ serialization software offered as an integrated solution within Autajon’s exhibit booth #2P16 (Hall 2).

CPhI Worldwide, together with co-located events ICSE, InnoPack, P-MEC and FDF, will host more than 36,000 visiting pharma professionals from 4-6 October at the Fira Gran Via, Barcelona, Spain. More than 2,500 exhibitors from 150+ countries gather at the event to network and take advantage of more than 100 free industry seminars. Every sector of the pharmaceutical market is represented under one roof, this year in a new location in Barcelona.

With thousands of implementations across the globe, Systech is the world’s most trusted brand protection expert, and its UniSeries offering is the industry standard for serializing products. UniSeries is offered as an integrated solution with both Sharp Packaging and Autajon Group’s hardware. Systech’s patented, configurable software offers manufacturers the flexibility to adapt to new regulations without extensive reworking or revalidation, thereby reducing implementation, training and support costs.

“We are recognized as the world leader in serialization and brand protection,” states Manfred Voglmaier, Senior Director Sales Europe, Systech International. “With more than 30 years of experience in providing highly configurable solutions for serialization across a variety of industries ― along with our partners Sharp Packaging and Sinel ― gives us a unique insight for this panel.”

Systech’s products are in greater demand than ever before since it is estimated that over 15,000 production lines for prescription medication in Europe must be fitted with a serialization system over the next three years. The European Commission adopted a regulation on October 2, 2015, under which the serialization of prescription medicine packages will become mandatory in all EU countries by 2019.

Show exhibit hours are on Tuesday, 4 October – Thursday, 6 October. Systech representatives will be available in the Sharp Packaging booth #3L56 (Hall 3) during the event, as well as in the Autajon booth #2P16 (Hall 2). They will showcase Systech’s software solutions on sample packaging lines and via live demos throughout the event.

SOURCE: EuropaWire

Finnish Servicepoint to resell, install and support Systech’s serialization solutions in Scandinavia, the Baltic States, and Russia

servicepoint-fi__logo_europawireFinland, 23-Sep-2016 — /EPR HEALTHCARE NEWS/ — Systech International, a global leader in brand protection technologies, today announces the extension of its strategic partnership with Servicepoint, a leading serialization automation supplier.

Systech has signed a global agreement with Servicepoint, allowing the company to act as a single point of contact for customers across Europe. Through this agreement, Servicepoint will now resell, install and support Systech’s serialization solutions to customers of any size across Europe, especially in Scandinavia, the Baltic States, and Russia.

This agreement comes at a critical time within the pharmaceutical industry, as the European market is growing exponentially. It is estimated that over the next three years, 15,000 production lines for prescription medication in Europe must be fitted with a serialization system. The European Commission adopted a regulation on October 2, 2015, under which the serialization of prescription medicine packages will become mandatory in all EU countries by 2019.

Systech and Servicepoint first engaged two years ago when jointly delivering serialization and automation/integration solutions to a pharmaceutical manufacturing client. As a result, both companies were able to offer enhanced solutions and increase their speed of delivery.

Servicepoint maintains and offers professional services, automation services, retrofit/upgrade services to Systech customers and provides Level 1 and 2 support, while Systech provides Level 3 support for the software.

“Servicepoint has a solid network of over 50 professionals in Europe, which, when combined with Systech’s growing regional support, creates a large and experienced talent pool for the delivery of serialization initiatives,” states Harry Saint-Preux, Director, Global Alliances & Channels, Systech International.

“Servicepoint has extensive expertise and a long history automating hundreds of production lines for different fields of industry and European pharmaceutical manufacturers, as well as experience with track-and-trace initiatives. Systech and Servicepoint’s combined approach provides manufacturers with the solutions, services and support required to address Europe’s challenging serialization requirements,” notes Saint-Preux.

Risto Finne, chairman of the board, Servicepoint, comments, “Servicepoint is honored to enter into this partner agreement with Systech, who we consider to be the global market leader in serialization. This cooperative paves the way for numerous new business opportunities, particularly with Russian companies that need to rapidly employ serialization. Our experience in integrating modifications and upgrades of existing production lines, in addition to new, turnkey, fully-automated solutions for the serialization and packing of medical, food and other sensitive products puts us in an enviable market position.”

Servicepoint is one of only a handful of suppliers in the European market that provides an all-inclusive production automation solution including planning, installation, testing, and maintenance.

SOURCE: EuropaWire

JobMedic.com Revolutionizing Healthcare Recruiting for Job Seekers and Employers

Houston, Texas, March 18, 2015 — /EPR HEALTHCARE NEWS/ — JobMedic.com is a new Houston-based company with a mission to improve healthcare recruiting. It is a new comprehensive web platform to find healthcare jobs and pair them with qualified candidates. JobMedic.com will serve as a new access point in the Healthcare Industry, providing relevant news summaries and information, career opportunities, company profiles, relevant career discussions, continued education and more.

“The need for a platform of this nature came to our attention when we found out there are currently thousands of unfilled jobs within the Texas Medical Center. We decided to create an evolved job board to better connect job seekers and employers within the Healthcare field for a more useful experience,” says Matt Bertram, Head of Business Development.

Different from other job-search engines, JobMedic.com serves as a talent acquisition platform and is an efficient way for employers to advertise healthcare positions and attract qualified job seekers.

Kyle Johnson, CMO & CTO at JobMedic.com, states, “Other job site platforms fail to cater to the needs of the healthcare industry and/or are extremely broad for recruiters to efficiently maneuver within a timely manner. We want to be the one-stop-shop for job seekers and employers under the healthcare umbrella to locate and place top candidates within the industry.”

For every approved resume that is uploaded, JobMedic.com will donate to the Doctors without Borders organization to support medical actions being conducted throughout 70 countries around the world. JobMedic.com will be running a campaign to raise $10,000 by July 2015.

Job Seeker, meet JobMedic. from JobMedic on Vimeo.

For more information, please visit our website for further details and a brief video that highlights all of the JobMedic.com functions: https://jobmedic.com/.

For all press inquiries please reach out to press@jobmedic.com

Via EPR Network
More Healthcare press releases

Health Gorilla Releases Mobile Application for Doctors

Digital Health Leader Expands Marketplace Access with Mobility

SUNNYVALE, CA., 2014-8-20 — /EPR Healthcare News/ — Health Gorilla™, Inc., the first online healthcare marketplace to connect doctors and clinicians with over 9,000+ diagnostic labs and 35,000+ radiology centers, has announced today the release of Health Gorilla mobile.  Health Gorilla mobile provides access to the Health Gorilla Marketplace through the Apple® iPhone® and iPad™.

Today over 68% of doctors have standardized on the Apple platform to communicate with peers and patients. Doctors can now use their mobile devices to place electronic orders with Health Gorilla mobile to diagnostic labs, radiology centers, physical therapy, skilled nursing facilities (SNFs) and durable medical equipment (DME) and other medical providers nationwide with the ability to track and review the results instantly as they arrive.  Physicians can then forward electronic results within their practice or exchange them with peers and patients to streamline the process and improve quality of care.

According to a study published by the New England Journal of Medicine noted that approximately 59.3% of all of a primary care physician’s daily emails were for the interpretation of test results and 21.7% were responses to patients.  The use of email generally increases the risk for doctors and their patients as most email services are not HIPAA compliant.

Another study published in the Journal of the American Medical Association (JAMA) reported that researchers from the Michael E. DeBakey Veterans Affairs Medical Center in Houston conducted a survey of primary care practitioners and found that a third reported missing alerts about test results from an electronic health record notification system designed to inform them when a patient has abnormal test results.

Doctors are adopting iPad and iPhones as the platform of choice to communicate with peers and patients. Health Gorilla mobile integrated messaging greatly reduces the risk in communication between a doctor and their patients by offering a fully HIPAA compliant environment. Health Gorilla mobile enables a physician to securely and compliantly forward diagnostic test results, radiology images, admission and discharge summaries and other clinical documents to patients and care coordinators through secure messaging.

Benefits of Health Gorilla Mobile Include:

  • HIPAA compliant and ONC modular certified MU2 solution
  • Order in less time than it takes to use fax forms
  • Receive results faster wherever you are
  • Forward results to patients instantly
  • Immediately refer results to another doctor and send messages
  • Eliminate error prone paper processes
  • Mobile solution available at no charge for doctors and their teams

“We believe that the value proposition is clear and compelling for doctors and their teams.” said Steve Yaskin, Chief Executive Office, Health Gorilla, Inc.  “The existing process is heavily dependent on paper, fax and manual processing.  It is slow, cumbersome and prone to error.  Doctors can better manage their time, and the time of their administrative and care coordinating teams, by using the power of the marketplace through the Health Gorilla app.  Now they have one place to order from any diagnostic lab, radiology center, hospital, physical therapy, sleep center, SNF and other healthcare providers in the United States.  A doctor can start with us the first day and begin ordering through the marketplace immediately.  Health Gorilla is the first to deliver this capability.  No other vendor can provide this benefit.”

Health Gorilla mobile is available as an approved Apple® enterprise application and will be distributed to existing Health Gorilla Marketplace users via a secure link for the next month.  In September Health Gorilla mobile app will be available from the Apple® store and will be fully integrated with the Apple® Health app upon its release.

About Health Gorilla
Health Gorilla™ is the first online healthcare marketplace to connect all doctors and clinicians with over 9,000+ diagnostic labs and 35,000+ radiology centers.  Doctors and their teams can instantly place orders, get results, and completely eliminate paper faxes. Uniquely, our HIPAA compliant and ONC modular certified MU2 solution is available immediately at absolutely no charge for doctors and clinicians.

Watch our 2 minute video Intro to Health Gorilla: http://youtu.be/6Luo5eNG8-s
Tweet: https://www.twitter.com/healthgorilla
Facebook: https://www.facebook.com/healthgorilla
LinkedIn: https://www.linkedin.com/company/2542523?
Sign-up for our Newsletter at the bottom of homepage:
http://www.healthgorilla.com

Contacts

For additional information contact Joe Austin via jaustin@theventanagroup.com or call 818-332-6166.

Health Gorilla™ is a trademark of Health Gorilla, Inc.
Apple®, iPhone®, iPad mini™ are trademarks of Apple, Inc.

Health Gorilla Releases Mobile Application for Doctors
Health Gorilla Releases Mobile Application for Doctors

HD Biosciences, Co., Ltd. and E. J. Corey Institute of Biomedical Research Reached Agreement for Drug R&D Collaboration

HD Biosciences Co., Ltd. (HDB) and E. J. Corey Institute of Biomedical Research (CIBR) announced that they have reached a risk-sharing agreement on collaborative drug discovery and development in the therapeutic areas of infectious diseases, metabolic diseases, and oncology. This joint effort will focus on both international and Chinese markets to provide innovative medicines for unmet healthcare needs. The agreement includes lead candidate selection pre-clinical development, IND filing, clinical trials, and NDA approvals. Both companies will share financial returns from any successes or products launches.

“We are delighted to enter this partnership. The collaboration will leverage HDB’s extensive capabilities in preclinical drug discovery and development, and create long term potentials for the company.” stated Xuehai Tan, Ph.D., President & CEO of HDB. “In combination of CIBR’s expertise in drug development, we are confident to deliver novel drug candidates over the next few years, and to make this partnership a success.”

“Working with HDB gives CIBR a unique opportunity to showcase its strength in innovative drug discovery and development,” said Wuyi Meng, Ph.D., President of CIBR. “This partnership further demonstrates CIBR’s commitment in the betterment of patient’s lives by bringing forward novel medicines. We will collaborate closely with HDB to accelerate the progress of our collaborative programs”

About HD Biosciences Co., Ltd.
HD Biosciences Co., Ltd. is a Shanghai-based, biology-focused preclinical drug discovery contract research organization (CRO). The company offers comprehensive service platforms around target validation, plate-based pharmacology, hit identification and lead discovery, therapeutic antibody discovery, in vivo pharmacology, as well as other research and development services. The company currently collaborates with eight of the ten largest pharmaceutical companies in the world and has established strategic partnerships on many key R&D areas with impacts to their portfolios. The strong scientific expertise, high quality and consistency in deliveries, constantly meeting or exceeding expectations, has earned the company a great reputation in the industry, and helped the company to build its widely recognized leadership in preclinical contract research services.http://www.hdbiosciences.com

About E. J. Corey Institute of Biomedical Research
Located in the Jiangyin High-tech Industry Development Zone in Jiangyin, Jiangsu, E. J. Corey Institute of Biomedical Research (CIBR) is a non-profit research organization founded by Nobel laureate Prof. E. J. Corey with the support from Jiangyin and Jiangsu government. CIBR is committed to scientific research in the broad biomedical field and to the development of novel therapeutics to meet the unmet medical needs of patients. In addition to its strong internal research and discovery capabilities in biomedical research and drug discovery, CIBR has established solid external capabilities in translational medicine and molecular toxicology to support drug development. Under the guidance of Nobel laureate Prof. Corey, CIBR is well poised to contribute to the discovery and development of novel medicines. http://www.cibrnobel.org

Contact Details:
HD Biosciences
Ms. Jessie Yang
Email: yangxiaojie@hdbiosciences.com

CIBR
Dr. Jiaquan Wu;
Email: jwu@cibrnobel.org

 

Via EPR Network
More Healthcare press releases

EMS Healthcare receives ISO accreditation for fourth consecutive year

EMS Healthcare has announced that it has achieved ISO accreditation for the fourth consecutive year.

It is the latest in a long line of endorsements that the UK event marketing organisation has achieved continuously and maintained over the years. It marks EMS Healthcare as a first-class employer.

By investing in standards of best practice, EMS Healthcare not only gives their customers peace of mind and the confidence to do business with them, but they are also able to recruit the best and brightest talent in the event trailer hire and mobile medical accommodation industry.

Ultimately, it strengthens our proposition to both existing clients and prospects; whilst also helping to strengthen their ongoing recruitment drive. Ultimately it makes good business sense all round.

David Legg, Finance Director at EMS said: “We may be a SME business, but we are perfectly formed and certainly have big company values.

“When it comes to our staff, this is no exception, and we’re delighted to have recently passed the BS OHSAS 18001:2007 – Occupational Health and Safety Standard, which is no mean feat.

“It’s the fourth consecutive year that we have achieved the accreditation. And we were among one of the first live events companies to lead the way in its attainment.”

Find out more about EMS Healthcare and mobile medical accomodation today by calling 0151 350 1500 or visiting http://ems-healthcare.com.

Via EPR Network
More Healthcare press releases

Providing Personalized Service to Clients in Need of Health Insurance Solutions

Loyal Leaf™ is in the business of providing tailored, personalized service to clients in need of health insurance solutions. They take pride in being insurance guides who provide one-stop, last-stop service by offering a complete range of products and professional service.

Their newly designed website has been reinvented in order to serve their client base better by providing a comprehensive assortment of insurance packages under one roof. It is designed to provide information, tools and education to those in search of health insurance. With an easy interface and improved navigation Loyal Leaf has created a naturally comfortable environment for the consumer. It is vital in the ever changing world of the health care industry that all information be current and viable and clearly stated. Loyal Leaf through its brand new website is doing its part to demonstrate their professionalism with their improved online presence. The inclusion of an information filled health-related blog rounds out the presentation.

Loyal Leaf’s insurance agents continue to have an advanced toolbox with which to compare both prices and products from a wide selection of top tier insurance carriers. They are very well versed on the latest Obama Care regulations and the advent of new and exciting product options for their client offerings.

Via EPR Network
More Healthcare press releases

HD Biosciences and Anchor Therapeutics Form Collaboration for Co-marketing Pepducin-mediated GPCR Technology

HD Biosciences Co., Ltd (HDB) and Anchor Therapeutics, Inc. today announced that they have formed a strategic collaboration to co-develop and co-market Anchor’s proprietary pepducin technology and provide novel drug development solutions to global pharmaceutical companies with drug discovery efforts focused on G-protein coupled receptors (GPCR).

Pepducins are proprietary lipidated peptide modulators for GPCR signaling. They may stabilize receptor conformation, promote or inhibit dimerization, and modulate interaction of GPCR with signalosome. As a strong research tool, pepducin technology enables high throughput screening (HTS) campaigns for the identification of special class of compounds and allosteric ligands, facilitates biophysical studies via stabilization of GPCRs in different activation states and functionally de-orphanizes GPCRs to provide tools for interrogation of pharmacology in vitro and in vivo.

As a key component of HDB’s plate-based pharmacology service capabilities, GPCR assays and screenings is one of the most active research and development areas that attracts global clients and partners in drug discoveries. With over 200 recombinant GPCR cell lines in house, some of which are orphan receptors, combining a variety assay formats with pepducin technology allows HDB to enhance its capabilities for supporting hit identification, lead discovery and receptor selectivity profiling. The collaboration is also designed to provide broader exposure and accessibility of pepducin technology across pharmaceutical and biotechnology industries through HDB’s global client base. HDB’s clients will gain unprecedented access to not only the pepducin screening platform but also HDB-Anchor’s joint expertise in GPCR research.

“Anchor’s pepducin technology has provided a novel approach to search very special GPCR related compounds that have potential to alter the receptor functions. We believe this technology will be very valuable in GPCR related drug discovery.” commented Dr. Xuehai Tan, President and Chief Executive Officer of HDB. “As one of the global leaders in biology focused contract research services, HDB emphasizes on innovative and scientific driven technologies in order to deliver extra value to our clients. The partnership between HDB and Anchor is a perfect example to demonstrate our commitment to grow the expertise and strengthen our leadership in GPCR R&D.” Dr. Tan continues his comments.

“Anchor Therapeutics is extremely pleased to partner its pepducin technology with HD Biosciences, one of the leading companies providing state of the art high throughput screening services to pharmaceutical and biotechnology clients,” said Thomas J. McMurry, PhD, Anchor’s Interim President. Dr. McMurry continued, “Through this collaboration, Anchor and HDB will expand the validation of pepducin high throughput screening probes in order to provide HDB’s clients with access to innovative screens designed to facilitate access to novel small molecule pharmacophores.”

Via EPR Network
More Healthcare press releases

BlueFire Marketing Announces Launch of New Healthcare Reminder Service

BlueFire Marketing, a fully integrated marketing firm, announced today the launch of a text message marketing reminder service for healthcare providers. This service allows them to automatically remind patients of upcoming appointments. This reduces time and cost for healthcare providers who manually and individually call patients to remind them of their appointments.

BlueFire Marketing recognizes changing trends in both the market and in consumer preferences. In the U.S., smartphone penetration has reached 54%, and is projected to hit 84% by 2016. This creates an opportunity to reach individuals and build 1-on-1 relationships at an incredibly low cost.

Curt Johnson, President of BlueFire Marketing, said, “The beauty of the smartphone era for retailers and healthcare professionals is that the cost of the marketing medium is paid for by the consumer. The more your marketing mix shifts towards digital, the lower your cost per thousand.”

Via EPR Network
More Healthcare press releases

Healthcare Outcomes Solutions Launches Patient Centered Enhanced Care Model to Reduce Healthcare Costs for Chronically Ill Patients of Self insured companies and improve their care

Healthcare Outcomes Solutions (HOS), a company dedicated to reducing health care costs for self insured companies and their employees, recently launched its Patient Centered Enhanced Care model (PCEC). PCEC is a care coordination model designed to improve health care and reduce costs specifically for employee-patients, or their family members, with multiple chronic illnesses who are in a health plan offered by self-funded companies.

It is now common knowledge that approximately 5% of members of health plans account for about 50% of the cost. Multiple chronic diseases are the source of the majority of the cost in healthcare. The PCEC model enables self-funded businesses across the U.S. to offer coordinated care specifically for these member-patients. This service is offered to middle size or larger employers.

The PCEC model has been developed by healthcare experts and is grounded in extensive research of evidence-based and outcomes studies, many of which are available on the HOS website, www.healthcareoutcomes.net. The latest data on healthcare costs show that care coordination of the most chronically ill member-patients can reduce a company’s healthcare costs significantly.

We will work with companies to determine if the PCEC model is right for them. Affiliated healthcare accountants will examine a company’s current health care expenses, and HOS will determine the feasibility of reducing cost while improving care.

Via EPR Network
More Healthcare press releases

Napier Healthcare sets up US operations to address the needs of healthcare providers in North America

Healthcare software solutions specialist continues its international expansion with the establishment of a wholly-owned subsidiary in the United States. The new entity will focus on driving adoption of Napier’s suite of solutions across the healthcare spectrum, including general and specialty hospitals, clinics, laboratories and blood banks.

Singapore, May 16, 2013- Napier Healthcare Solutions (www.napierhealthcare.com), a leading healthcare software provider, is pleased to announce that it has set up a wholly-owned subsidiary in the United States, Napier Healthcare Solutions, Inc.

To be based out of New Jersey, the six-member US team will be headed by Manish Mehta, an industry veteran, who will be taking charge as General Manager for the services business across America. The US entity will focus on customer acquisition across the United States and other markets in North America.

“Setting up of US operations is part of our two-pronged geographical expansion strategy, wherein we are aggressively growing our reach across emerging markets such as Africa and also establishing our footprint in developed markets such as the United States,” said Karthik Tirupathi, CEO of Napier Healthcare. “This is an important milestone in our goal to be a global provider of leading-edge software solutions for the healthcare sector.”

Targeting the US market closely follows the roll-out of Napier’s next-generation fully mobile-enabled platform Napier EHRm. This open-source based platform provides hospitals and other healthcare providers scalability, flexibility, ability to integrate with 3rd party systems and lower their total cost of ownership (TCO).

“With the new enhanced mobile platform, we are confident of offering healthcare providers in the US with a suite of solutions suitable for their diverse requirements. We believe it will be an important differentiator,” adds Karthik.

Via EPR Network
More Healthcare press releases

Innovative Drug Discovery Business, Biosortia Pharmaceuticals, Lands Two Health Care Veterans

Kurt Dieck formerly SVP of Strategy and Business Execution at Cardinal Health, will lead early stage drug discovery business at Biosortia Pharmaceuticals. Dieck was named President and CEO in November 2012 and has quickly identified other key executives, including Dr. Guy Carter, former Natural Product head at Wyeth Pharmaceuticals, as his Chief Science Officer. In conjunction, other collaboration partners have joined the team, including NOAA (National Oceanic and Atmospheric Administration), NCI (National Cancer Institute) and key universities, to strategically accelerate the development of novel drug leads in the therapeutic areas of cancer, infectious diseases, inflammation and neurological disorders. Biosortia Pharmaceuticals has seen promising early results with dozens of novel compounds having already been requested, and are under evaluation with NCI and Eli Lilly.

Dieck has spent nearly 30 years in healthcare, including 18 years at Arthur Andersen as a global equity partner and then 10 years with Cardinal Health, a Fortune 20 public company, as a senior executive; there he worked with a broad spectrum of partners, including brand pharmaceutical manufacturers, throughout the supply chain. Dr. Guy Carter has over 30 years of experience working in pharmaceutical R&D, primarily in the discovery and development of microbial natural products. He previously was the leader of natural products drug discovery at Wyeth Research, as head of the Chemical Technologies Department.

“Kurt and Guy make a great team. Their complementary Pharma experiences and backgrounds create great opportunities to accelerate Biosortia’s objective to become the premier, aquatic natural products company with a primary focus in drug discovery,” says Ross Youngs, Biosortia’s Founder and Chairman. “Kurt and Guy bring a wealth of research and business experience along with deep industry relationships in building successful Pharma partnerships. Everyone involved with this young biotech is excited about the future.”

Industry observers have commented that late-stage R&D pipelines are not providing Pharma with the desired revenue growth the market is expecting. Therefore, large Pharma is evolving the way it performs R&D in order to optimize efficiency and to boost patent cliff defenses. These changes require shifting from relying solely on in-house chemistry-based R&D to acquiring and licensing external technologies and natural products based compounds in various stages of development. Biosortia’s ability to supply novel, highly active and potent compounds with drug-like characteristics will increase the productivity and success rate for Pharma as well as reduce the overall cost of the discovery process. The cost to discover, develop and launch a new drug is estimated to reach nearly $3B per drug by 2015. Biosortia’s business model is designed specifically to support Pharma’s needs.

“With nearly unlimited microorganisms (3.7 nonillion), the aquatic environment and its consortia represent an extraordinary opportunity…a new frontier, to access extremely potent and chemically diverse secondary metabolites with drug-like properties with unique mechanisms of action never researched before,” said Dieck. In describing the opportunity, Dieck goes on to say, “Biosortia is on the cutting edge of natural product discovery
and has the capabilities to deliver on its aspiration. Our powerful natural products research team, led by Dr. Guy Carter, in partnership with NOAA’s Dr. Peter Moeller, a leader in aquatic natural products research, has the experience and know-how to decipher the complex unexplored environment in a very efficient manner leveraging all the current state of the art instrumentation. The need for more efficient and effective approaches to drug discovery has never been more important. Biosortia’s innovative technologies, deep research skills and key relationships will efficiently provide thousands of unique natural products as candidates for drug discovery at a time when Pharma is in critical need for “high quality shots on goal.”

“Aquatic microbial consortia are a rich source of metabolically active organisms including microalgae, bacteria, fungi and their secondary metabolites,” states Carter. “Owing to the competitive nature of their habitat, chemical investigations of microbial consortia reveal unique structurally diversified natural products that are responsible for signaling and self-defense that have potential as therapeutics with novel mechanisms of action. Since they have been pre-optimized by nature, these compounds are typically closer to a drug candidate than a synthetic lead, thus requiring less optimization and shorter time when found as ‘hits’ in screening programs.”

The team has also focused on agreements with strategic collaboration partners as vital components to the strategy. Biosortia has recently entered into several collaboration agreements with NOAA, Analyticon and exclusive harvesting relationships, just to name a few. Several others will be advanced by the end of January. Biosortia’s cooperative research and development agreement (CRADA) with NOAA’s Center for Human Health Risk at Hollings Marine Laboratory provides a 5-year framework for research and development regarding the analysis and purification of novel bioactive compounds. According to NOAA’s Technology Partnerships Office, “Success will result in the commercial development of new and unique chemical compounds from the sea which have benefits to human health, either through disease prevention or new treatments for disease.”

Dr. Peter Moeller, NOAA’s Research Scientist who leads the Toxins Natural Products Program stated after analyzing fractions of Biosortia’s biomass, “Coupling NOAA’s mission of characterizing toxins affecting environmental and/or human health with Biosortia’s drug discovery focus turns one man’s toxin into another’s chemotherapeutic. The microorganisms analyzed in the Biosortia biomass identified more unique activity than I have seen in my 30 year career. The volumes achieved from a single harvest delivered an equivalent of 30 years of accumulation. This could materially change the landscape for natural products drug discovery research.”

As of December 31, 2012, Biosortia has identified more than 30 bioactive candidate compounds (hits) from a fresh water eutrophic lake consortium. Therapeutic areas of focus include treatments for cancer, infectious diseases, inflammation and neurological disorders. In addition, more than a dozen of its patent protected compounds are in initial evaluation stage within Eli Lilly’s Open Innovation Drug Discovery Program.

Dieck states, “Looking forward, it is with great optimism. We have a great team built around mutual respect, deep experience, and a desire to succeed and make a difference. We are aligning with the right partners and collaborators to execute our strategy with speed and discipline to provide Pharma with much high quality & diverse compounds vs. “me-too” drugs than they have had in the past 10 years. We are excited about what this company can accomplish, not only for its shareholders but also for the millions of people who have been diagnosed with various forms of chronic diseases who are looking for Pharma to identify better ways to help them extend their lives or live a more productive life. Biosortia can play a big role in identifying compounds that can help Pharma achieve these goals. I am looking forward to the challenge and opportunity to build an industry leading drug discovery company.”

Via EPR Network
More Healthcare press releases

Microtissues® Inc. and Sigma-Aldrich® Sign Worldwide Supply and Distribution Agreement for the 3D Petri Dish®

Microtissues® Inc. announced today the signing of a Supply and Distribution Agreement with Sigma-Aldrich® Corporation (Nasdaq: SIAL) for the worldwide sales and marketing of the 3D Petri Dish®, a new technology for the culture of living cells in three dimensions (3D). Invented at Brown University, the 3D Petri Dish® maximizes cell-to-cell interactions critical for replicating the function of natural tissues and organs. Shown in numerous peer reviewed papers to work with over fifty different cell types, including cell lines, primary cells and stem cells, the 3D Petri Dish® has applications in cancer research, drug discovery, toxicity testing and regenerative medicine.

“Researchers are rapidly recognizing the importance of 3D cell culture and its ability to reliably mimic in vivo function” said Brian Morgan, Director of Business Development, Microtissues® Inc. “The 3D Petri Dish® creates a natural 3D environment without artificial scaffolds and we’re excited that this distribution agreement will bring our unique and innovative line of products to the worldwide research community.”

Unlike the conventional plastic Petri dish where cells are grown as a thin layer on the surface of the dish, the 3D Petri Dish® forms 3D aggregates of cells. Spheroid size is controlled by the number of cells seeded and hundreds of uniform sized spheroids are formed in a single pipetting step. Spheroids are formed in a well ordered array in a stable platform suitable for long term culture. All spheroids are positioned on the same optical plane making them easy to image (phase contrast, fluorescent). Spheroid size is controlled by the number of cells seeded and a mixture of cells forms mixed spheroids, suitable for investigating tumor-stroma interactions. Spheroids can be grown from single cells, applicable to the study of cancer stem cells. For histology, Western blots and RT-PCR, spheroids are harvested by simply inverting the 3D Petri Dish®. No need to dissolve or digest the gel. The 3D Petri Dish® is a new fundamental tool for the world wide industry of life sciences research.

About Sigma-Aldrich®: Sigma-Aldrich® is a leading Life Science and High Technology company whose biochemical, organic chemical products, kits and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostics and high technology manufacturing. Sigma-Aldrich® customers include more than 1.3 million scientists and technologists in life science companies, university and government institutions, hospitals and industry. The Company operates in 38 countries and has nearly 9,000 employees whose objective is to provide excellent service worldwide. Sigma-Aldrich® is committed to accelerating customer success through innovation and leadership in Life Science and High Technology. For more information about Sigma-Aldrich®, please visit its website at www.sigma-aldrich.com.

About Microtissues® Inc: Microtissues® Inc. is a privately held company located in Providence, RI, advancing technologies and applications of 3D cell culture. Microtissues®, Inc.’s products are designed to serve the needs of researchers in a wide range of areas including cancer research, stem cell biology, toxicity testing, developmental biology, drug discovery, regenerative medicine and tissue engineering. Microtissues®, Inc. has an exclusive worldwide license from Brown University to US and international patent applications on the 3D Petri Dish®. For more information on Microtissues®, Inc., please visit www.microtissues.com.

Sigma-Aldrich and Sigma are trademarks of Sigma-Aldrich Co. LLC registered in the US and other countries. Microtissues and 3D Petri Dish are registered trademarks of Microtissues, Inc.

Via EPR Network
More Healthcare press releases

Centralized Sent Mail Folder for Crypt-n-Send, Email Encryption Service

MDofficeMail is proud to announce the release of new version of Compose-Webpage, Webmail, iPhone/iPad App and Android App for their HIPAA compliant Email Encryption Service, Crypt-n-Send.

Most advanced and advantageous feature of this new version is- Centralized Sent Mail folder.

With most of the email services, when email messages are sent from webmail, Outlook/other email client applications or smart phone email programs, messages sent are stored in different folders. For example if you have sent a message from Outlook of your home computer, you don’t have access to that message unless you have access to that particular computer.

To overcome this common problem, CryptnSend adopted a new software technology.

Secure email messages sent using any of the below given methods are saved in to the Sent Mail folder of your Webmail. Further, this folder can be accessed directly from your smart phone and Compose-Webpage without logging into your Webmail:
A. Compose-Webpage: Browse https://cryptnsend.com, compose a secure message, and send.
B. Webmail: Browse https://secure.cryptnsend.com, login, compose a secure message, and send.
C. iPhone/iPad and Android App: Download and install the app, login with your email id and password, compose and send message.
D. MS Outlook/Apple Mail/Any other Email Client program: Configure your CryptnSend account in your email client program and send secure, encrypted messages.

About Crypt-n-Send Email Encryption Service from MDofficeMail
To send any confidential information like PHI by email, it is necessary that
a)Both the sender and the recipient should have a secure email account.
b)The content of the message should not be in human readable format if it is accessed by someone else.

In general, many responsible senders like medical facilities will have secure email service at their end. However, they ignore the importance of security at recipient’s end. It is a known fact that majority of people use free accounts with no security at all. To handle this critical issue that is most often ignored, to maintain the end-to-end security of emails, MDofficeMail is presenting to you Crypt-n-Send.

Crypt-n-Send is an innovative service for encrypting and delivering email with end-to-end security. You can use any email account to SEND secure email. The recipient’s email account need not be secure.

In addition, this process doesn’t involve the hassle of installing additional software, security certificates, or keys. However if you choose MS Outlook to send secure and plain messages, you can install Crypt-n-Send Add-in for MS Outlook as an option.

How Crypt-n-Send works
Continue to use your existing email account as before and subscribe to Crypt-n-send service for your existing email id.

Other important features of Crypt-n-Send include:
New recipient validation: By selecting this option while composing a message, the sender can restrict a new recipient from viewing the message without a security token. This token can be given to the recipient over phone.

Password reset authorization: Unless the sender authorizes, recipient cannot reset a forgotten password to view a secure message.
Validation of recipient to reset password: Optionally, the sender can validate the recipient requesting for a reset of a forgotten password.

Sender has the option to send encrypted message or plain message to any email recipient.

Access logs: Access logs can be viewed for each user, as required by HIPAA

Force expiration of sent messages: In case incorrect information is emailed by error, sender can force expire the message. Force expired message will no longer be available to the recipient.

Fixed life of sent message: Messages are automatically deleted from MDVault after 30 days irrespective of whether it is already viewed by the recipient or not.

Downloading and storing: If the recipient wants to save important messages for future reference, they can download and save the message on their computer.

Secure reply: Recipient of a secure message can send a secure, encrypted reply.

Automatic session time-out.

Change-Password Reminder: Users are reminded to change their password every 90 days to maintain the HIPAA compliance.

Attachments: Attachments can be sent using Compose Webpage, Webmail and MS Outlook.
Attachments are encrypted and can be downloaded from MDVault secure site. Recipients can include attachments in their replies as well.

Limitations with Crypt-n-Send Service from MDofficeMail:
Message headers, including the subject are not encrypted and will get delivered to the recipient in the notification. Be careful not to include sensitive information in the subject line.

Messages held by MDVault will be removed after 30 days for better security. So, it can’t be used as a long-term secure message storage.

Sign up for Crypt-n-Send service from the following link:https://cryptnsend.com/SecureOrder.aspx

For more information on Crypt-n-Send and MDofficeMail Email Hosting Service, please visithttp://MDofficeMail.com

Encryption technology used in Crypt-n-Send and MDofficeMail Email Hosting Service:

MDVault uses industry-standard AES-256 encryption in CBC mode with MD5 hash. Many federal agencies and financial institutions around the globe use the same class of encryption to protect very sensitive data. AES-256 encryption is so secure that there are no publicly-known attacks that will recover anything useful from an AES-256 encrypted file in any remotely reasonable amount of time.

Via EPR Network
More Healthcare press releases

Vitamin D Pharmacy’s YouTube Video Surpasses the 2000 View Mark as Winter Sets in and the Hours of Vitamin D Producing Sunshine Decrease

New Life Pharmacy in Glasgow is on a mission to raise awareness of vitamin D deficiency and in turn, reduce the number of people suffering from its related health issues.

In April 2012 Elizabeth Roddick, Fellow of the Royal Pharmaceutical Society of Great Britain, pharmacist and owner of the New Life Pharmacy released a video on YouTube that explains the health risks of being deficient in vitamin D. Low levels of this important vitamin have been linked with diabetes, arthritis, high blood pressure, hypothyroidism and cancer.

More recently, studies have found that a high level of vitamin D in women under the age of 75 can decrease the risk of macular degeneration and the loss of central vision, which is a main cause of partial-blindness in people over 50 years old (Qureshah, 2012). Vitamin D deficiency can also lead to health issues and diseases such as rickets, multiple sclerosis, depression and respiratory tract infections.

Vitamin D is produced when ultra violet (UVB) rays coming from the sun hit the skin. It is then absorbed through the liver where it is converted to calcidiol. It then works to check the calcium and phosphate levels in the blood, which are important for maintaining healthy bones. Vitamin D can also be found in some foods such as eggs, oily fish and fortified cereals.

It is common knowledge that all people’s vitamin D levels drop during the winter (November to March) as the sun is weaker during this time. A recent study (Qureshah, 2012) found that during the winter 28 percent of women had deficient levels of vitamin D, and 33 percent of women had insufficient levels. Being regarded as deficient means the level of vitamin D is less than 20ng/mL, insufficient is having 20-29ng/mL. Compare this with the summer statistics where only 5% are deficient in vitamin D and the contrast is clear.

According to Roddick, the skin needs to be exposed at the hottest time of the day (between 10am and 3pm) for about 15 minutes. These are the hours where the UVB rays are strongest and so vitamin D is most prevalent. This of course completely opposes the advice given out by skin cancer charities who urge sun bathers and holiday makers to stay out of the sun during these peak hours. Roddick does add, “It is of course very important than the skin does not burn since that can lead to skin cancer.”

Roddick believes that, “supplementation is required for most people. Also, because there are certain people who shouldn’t take vitamin D and a wide range of doses are available it can be confusing. Advice needs to be available when purchasing the products.”

Via EPR Network
More Healthcare press releases

Smart Phone App to Send HIPAA Compliant, Encrypted Email from Crypt-n-Send Service

MDofficeMail is proud to announce the release of iPhone/iPad App and Android App for their HIPAA compliant Email Encryption Service, Crypt-n-Send.

By installing this app iPhone/iPad and Android phone users can send encrypted email messages from their smart phones.

About Crypt-n-Send Email Encryption Service from MDofficeMail:

To send any confidential information like PHI by email, it is necessary that
a) Both the sender and the recipient should have a secure email account.
b) The content of the message should not be in human readable format if it is accessed by someone else.

In general, many responsible senders like medical facilities will have secure email service at their end. However, they ignore the importance of security at recipient’s end. It is a known fact that majority of people use free accounts with no security at all. To handle this critical issue that is most often ignored, to maintain the end-to-end security of emails, MDofficeMail is presenting to you Crypt-n-Send.

Crypt-n-Send is an innovative service for encrypting and delivering email with end-to-end security. You can use any email account to SEND secure email. The recipient’s email account need not be secure. In addition, this process doesn’t involve the hassle of installing additional software, security certificates, or keys. However if you choose MS Outlook to send secure and plain messages, you can install Crypt-n-Send Add-in for MS Outlook as an option.

How Crypt-n-Send works:

Continue to use your existing email account as before and subscribe to Crypt-n-send service for your existing email id.
Send secure messages in four different ways:
A. Compose Webpage: Browse https://cryptnsend.com, compose a secure message, and send.
B. Webmail: Browse https://secure.cryptnsend.com, login, compose a secure message, and send.
C. iPhone/iPad and Android App: Download and install the app, login with your email id and password, compose and send message.
D. MS Outlook: Download, Install and Configure the Add-in from http://mdofficemail.com, follow instructions to send secure and encrypted messages from MS Outlook.

Other important features of Crypt-n-Send include:

1. New recipient validation: By selecting this option while composing a message, the sender can restrict a new recipient from viewing the message without a security token. This token can be given to the recipient over phone.
2. Password reset authorization: Unless the sender authorizes, recipient cannot reset a forgotten password to view a secure message.
3. Validation of recipient to reset password: Optionally, the sender can validate the recipient requesting for a reset of a forgotten password.
4. Sender has the option to send encrypted message or plain message to any email recipient
5. Access logs: Access logs can be viewed for each user, as required by HIPAA
6. Force expiration of sent messages: In case incorrect information is emailed by error, sender can force expire the message. Force expired message will no longer be available to the recipient.
7. Fixed life of sent message: Messages are automatically deleted from MDVault after 30 days irrespective of whether it is already viewed by the recipient or not.
8. Downloading and storing: If the recipient wants to save important messages for future reference, they can download and save the message on their computer.
9. Secure reply: Recipient of a secure message can send a secure, encrypted reply.
10. Automatic session timeout.
11. Change-Password Reminder: Users are reminded to change their password every 90 days to maintain the HIPAA compliance.
12. Attachments: Attachments can be sent using Compose Webpage, Webmail and MS Outlook. Attachments are encrypted and can be downloaded from MDVault secure site. Recipients can include attachments in their replies as well.

Limitations with Crypt-n-Send Service from MDofficeMail:
Message headers, including the subject are not encrypted and will get delivered to the recipient in the notification. Be careful not to include sensitive information in the subject line.

Via EPR Network
More Healthcare press releases

Boots UK and Macmillan Cancer Support launch new role to help millions access cancer information

According to new research* almost a third of people affected by cancer felt that they had insufficient information and support outside of their healthcare team. Boots UK and Macmillan have specially trained over 500 Boots Macmillan Information Pharmacists to help improve the lives of those affected by cancer**. They will be available in many Boots stores to help connect people to information and support in their local area.

The launch of the Boots Macmillan Information Pharmacist is the first time that the role of a pharmacist has been extended to include this type of cancer information and support. It is estimated that 2 million people are currently living with or beyond cancer in the UK and this is anticipated to increase to 4 million by 2030***. As the demand for cancer health care is set to rise, the launch of this innovative pharmacy role aims to help the millions of people affected by cancer access the information and support they need, in an accessible and trusted environment.

Ciarán Devane, Chief Executive of Macmillan, commented: “The Boots Macmillan Information Pharmacists are the next stage in what is already a strong and sector-leading partnership that we both are extremely proud of. Macmillan and Boots UK believe that by sharing expertise and working together, we can reach even more of the millions of people affected by cancer than we are currently.”

The research also showed that nearly three quarters (74%) of people living with cancer felt that the information and support they received outside of their healthcare team made them better equipped to understand their cancer experience:
– 92% felt it had a positive impact on their emotional, physical or financial well being
– 51% felt able to understand more about their cancer and their experience of it
– 48% felt able to make decisions that were right for them

Alex Gourlay, Chief Executive of Health & Beauty Division, Alliance Boots, added:
“The introduction of the Boots Macmillan Information Pharmacist means that for the millions of customers that visit Boots pharmacies across the country, they can access increased cancer information and support. The findings from this research highlight just how important accessing the right information at the right time can be for people affected by cancer and the role it can play in helping them to manage their condition.”

Visit www.boots.com/cancer to find your nearest Boots Macmillan Information Pharmacist. For cancer support contact Macmillan on 0808 808 0000 or visit www.macmillan.org.uk.

Via EPR Network
More Healthcare press releases

BootsWebMD.com launches Baby Personality Quiz

BootsWebMD.com has launched a new, online Baby Personality Quiz which highlights several key traits to look out for when analysing a baby’s temperament.

With the help of the Baby Personality Quiz* on the BootsWebMD.com Children and Parenting Health Centre, users can identify their baby’s personality by answering a series of simple questions about their behaviour. The results of the quiz can then be analysed to identify their behaviour patterns. Essential information about the best approach in managing a child’s behaviour habits can also be found, with a simple step-by-step guide to keeping in sync with the baby. It could even help users to work in tandem with their child’s temperament and personality to make life easier for both parent and child.

Whether the child is feisty or easy-going, the answer to identifying its personality and behaviour patterns lies in a number of key areas. According to paediatrician Dr William Carey, author of ‘Understanding Your Child’s Temperament’, these include:

Activity/energy level – if the child has high or low energy levels, parents need to look for ways to keep them moving at a pace that’s comfortable for them Approach to newness – a naturally hesitant or shy baby will need extra reassurance and patience to overcome their shyness.

Intensity – if a baby is laid back, they can get lost in the shuffle of family life and vice versa. If the baby is intense they must be taught to deal with the curves of life

Sensitivity – if a baby has high sensitivity to lights, noise or texture, parents must be patient and look for ways to avoid sensory overload such as the lighting and the type of clothes the baby wears.

Regularity – if everything is unpredictable, potty, naps, moods, parents have to let go of their controlling ways and loosen up. Conversely, if a baby likes structure, parents might have to adhere to the schedule they crave

Persistence – puzzles are great tools to lengthen attention span, along with a daily dose of bedtime reading.

Overall mood – parents should take the time to observe their baby’s daily patterns and what makes them smile for a happier baby.

Via EPR Network
More Healthcare press releases